SG&A Expense (TTM) Chart

View SG&A Expense (TTM) for BNTX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (TTM) Chart
Start Trial

Historical SG&A Expense (TTM) Data

View and export this data back to 2020. Start Trial.
Date Value
June 30, 2026 833.57M
March 31, 2026 759.44M
December 31, 2025 709.95M
September 30, 2025 597.23M
June 30, 2025 589.02M
March 31, 2025 631.04M
December 31, 2024 648.03M
September 30, 2024 643.05M
June 30, 2024 650.58M
March 31, 2024 605.95M
December 31, 2023 603.23M
September 30, 2023 607.55M
June 30, 2023 589.53M
Date Value
March 31, 2023 593.59M
December 31, 2022 570.29M
September 30, 2022 600.12M
June 30, 2022 538.05M
March 31, 2022 454.41M
December 31, 2021 393.84M
September 30, 2021 274.79M
June 30, 2021 214.27M
March 31, 2021 164.69M
December 31, 2020 125.32M
September 30, 2020 74.29M
June 30, 2020 42.04M
March 31, 2020 17.96M

SG&A Expense (TTM) Range, Past 5 Years

View SG&A Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (TTM) Benchmarks

View SG&A Expense (TTM) Benchmarks
Start Trial
Moderna, Inc. 965.00M
Biodexa Pharmaceuticals Plc 6.375M
NuCana Plc 7.064M
Mereo BioPharma Group Plc 19.44M
MediGene AG --